Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal sintilimab for hepatobiliary cancers with malignant ascites
ChiCTR2500099190Phase 2Recruiting
- Sponsor
- Jinling Hospital
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of sintilimab in hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and gallbladder cancer (2 arms), sponsored by Jinling Hospital. Primary endpoints: Overall survival and Safety. Started Mar 2025; status: recruiting.
02
Drugs
sintilimab
03
Conditions
hepatocellular carcinoma (HCC)intrahepatic cholangiocarcinoma (ICC)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2500099190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099190.